Skip to content

Quoin Pharmaceuticals Ltd.: 10-Q filed 2026-08-14

What Quoin Pharmaceuticals Ltd. reported in its quarterly report filed 2026-08-14 (fiscal Q2 2026): 28 published measures, 76 facts as tagged in accession 0001104659-26-097064.

This filing

Form
10-Q (quarterly report)
Filed
2026-08-14
Fiscal period
fiscal Q2 2026
Accession
0001104659-26-097064 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Quoin Pharmaceuticals Ltd. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2026-06-3011,969,562USD
At 2025-12-3120,390,569USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2026-06-308,036,891USD
At 2025-12-317,270,663USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2026-06-303,932,671USD
At 2026-03-318,773,132USD
At 2025-12-3113,119,906USD
At 2025-06-302,551,357USD
At 2025-03-315,925,809USD
At 2024-12-319,204,673USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2026-06-303,845,606USD
At 2025-12-313,818,096USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-5,371,042USD91
2026-01-01 to 2026-06-30-10,368,777USD181
2026-01-01 to 2026-03-31-4,997,735USD90
2025-04-01 to 2025-06-30-3,695,938USD91
2025-01-01 to 2025-06-30-7,508,117USD181
2025-01-01 to 2025-03-31-3,812,179USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-8,013,263USD181
2025-01-01 to 2025-06-30-6,280,510USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-95,965USD181
2025-01-01 to 2025-06-30-127,042USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2026-01-01 to 2026-06-308,136,707USD181
2025-01-01 to 2025-06-304,452,701USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2026-06-30-81,339,224USD
At 2025-12-31-70,970,447USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2026-01-01 to 2026-06-30977,476USD181
2025-01-01 to 2025-06-30681,843USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2026-06-3011,636,228USD
At 2025-12-3120,007,235USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2026-06-306,613,158USD
At 2025-12-315,546,930USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2026-06-303,109,517USD
At 2025-12-311,262,222USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2026-06-30333,334USD
At 2025-12-31383,334USD

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2026-04-01 to 2026-06-301,846,406USD91
2026-01-01 to 2026-06-303,543,854USD181
2025-04-01 to 2025-06-301,742,594USD91
2025-01-01 to 2025-06-303,325,632USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2026-04-01 to 2026-06-303,627,168USD91
2026-01-01 to 2026-06-307,060,930USD181
2025-04-01 to 2025-06-302,050,585USD91
2025-01-01 to 2025-06-304,424,724USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2026-06-3070,294,615shares
At 2025-12-3152,441,360shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2026-06-303,845,606USD
At 2025-12-313,818,096USD
At 2025-06-301,668,492USD
At 2024-12-313,623,343USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2026-06-3085,272,477USD
At 2025-12-3184,090,966USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2026-06-30-582USD
At 2025-12-31-613USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2026-06-30333,334USD
At 2025-12-31383,334USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2026-06-301,423,733USD
At 2025-12-311,723,733USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2026-06-301,757,390USD
At 2025-12-312,538,457USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2026-06-30836,146USD
At 2025-12-311,261,974USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

PeriodValueUnitDays
2026-01-01 to 2026-06-30-10,368,777USD181
2025-01-01 to 2025-06-30-7,508,117USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2026-04-01 to 2026-06-30-5,371,465USD91
2026-01-01 to 2026-06-30-10,368,746USD181
2025-04-01 to 2025-06-30-3,695,938USD91
2025-01-01 to 2025-06-30-7,508,117USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2026-04-01 to 2026-06-3025,000USD91
2026-01-01 to 2026-06-3050,000USD181
2025-04-01 to 2025-06-3025,000USD91
2025-01-01 to 2025-06-3050,000USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2026-04-01 to 2026-06-30102,532USD91
2026-01-01 to 2026-06-30236,007USD181
2025-04-01 to 2025-06-3097,241USD91
2025-01-01 to 2025-06-30242,239USD181

Inspect the source

Entity
Quoin Pharmaceuticals Ltd. / CIK 0001671502
Captured
2026-09-21T17:23:21.592Z
SEC response SHA-256
2151f8b73d57a6fe9ca2f61e800771e9f36346bab50baeb75ac206654fb0a978

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001671502.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))